Table 4 Toxicities at or above grade 2 and their time of onset

From: A phase 1 study of tazarotene in adults with advanced cancer

Dose (mg)

Patient no.

Toxicity

Grade

Time of onset (weeks)

1.4

0101

Asthenia

2

4

  

Hypercholesterolaemia

2

8

 

0103

Hypercholesterolaemiaa

4

1

 

0201

Hypercholesterolaemia

2

8

2.1

0105

Asthenia

2

16

  

Vomiting

2

16

  

Hypercholesterolaemia

2

1

 

0206

Asthenia

3

6

  

Anorexia

2

4

2.8

0106

Anorexia

2

4

  

Abdominal pain

2

4

 

0107

Abdominal pain

2

4

  

Asthenia

2

4

 

0207

Asthenia

2

8

4.2

0208

Asthenia

2

8

 

0108

Anorexia

2

8

  

Nausea

2

8

  

Vomiting

2

8

  

Back pain

2

8

8.4

 

Nil

  

16.8

0111

Nauseab

2

2

  

Vomitingb

2

2

 

0210

Asthenia

2

2

  

Back pain

2

2

  

Hypertriglyceridaemiaa

2

2

  

Hypercholesterolaemia

3

12

25.2

0115

Dry skin

2

4

  

Cheilitis

2

4

  

Sore nose

2

4

  

Stiff joints

2

8

 

0116

Cheilitis

2

4

  

Back pain

2

4

  

Sore nose

2

8

  

Hypertriglyceridaemia

2

2

 

0117

Anorexia

2

4

  

Cheilitis

2

8

 

0214

Asthenia

3

8

  

Back pain

3

8

  

Myalgia

2

12

33.6c

0112

Hypercalcaemia

3

4

  

Joint stiffness

2

4

 

0113

Asthenia

2

4

 

0114

Cheilitis

2

2

  

Dry skin

2

2

 

0211

Headache

2

2

 

0212

Myalgia

2

2

 

0213

Hypertriglyceridaemia

4

2

  1. Grade 2 at baseline. bSingle episode, not assessed in the dosage-escalation decision. cOnly grade 2 toxicities occurring in the first 4 weeks are listed; numerous other grade 2 toxicities were seen at this dose level (see Table 3).